Sierra Oncology (SRRA) 10% owner Longitude Capital Partners III disposed of 2,155,801 shares
Insider transactions reported
Longitude Capital Partners III, LLC (10% owner at Sierra Oncology Inc., SRRA) reported that they disposed of 2,155,801 shares on Apr 27, 2022. After these transactions the filing shows 8,015 shares held indirectly (See footnote).
- Reporting person
- Longitude Capital Partners III, LLC
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Apr 27, 2022 | Other acquisition or disposition (J) | Common Stock1, 2, 3, ... | -2,139,771 | - | - | 0 indirect |
| Apr 27, 2022 | Other acquisition or disposition (J) | Common Stock5, 6, 7, ... | +16,030 | - | - | 8,015 indirect |
Holdings before and after
- Common Stock: 175,000 to 8,015 indirect, See footnote
Footnotes from the filing
- 1. Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Prime Fund, L.P. ( LPF ) to its general and limited partners.
- 2. The securities are held directly by LPF. Longitude Prime Partners, LLC ( LPP ), the general partner of LPF, may be deemed to have voting and investment power with respect to the shares held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting, investment and dispositive power over such securities. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
- 3. Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ( LVP III ) to its general and limited partners.
- 4. These securities are held directly by LVP III. Longitude Capital Partners III, LLC ( LCP III ) is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Each of LCP III, Mr. Enright, and Ms. Tammenoms Bakker disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
- 5. Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members.
- 6. These shares are held directly by Juliet Tammenoms Bakker.
- 7. These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.
- 8. These shares are held directly by Patrick G. Enright.
- 9. Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members
Transaction codes in this filing
- Other acquisition or disposition:
- Code J marks a transaction that fits no other code. The footnotes describe what happened.
FAQ
What did Longitude Capital Partners III report in this SRRA Form 4?
Longitude Capital Partners III, LLC (10% owner at Sierra Oncology Inc., SRRA) reported that they disposed of 2,155,801 shares on Apr 27, 2022. After these transactions the filing shows 8,015 shares held indirectly (See footnote).
How many SRRA shares does Longitude Capital Partners III hold after this filing?
The filing shows 8,015 shares held indirectly (See footnote) after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code J mean on an SEC Form 4?
Code J marks a transaction that fits no other code. The footnotes describe what happened.
Historical context for SRRA
Earlier insider filings at SRRA
- Apr 7, 2022SEC Form 4: Turner William D. exercised 6,447 shares at a strike of $12.05 and sold $240,118 worth of shares (6,447 units at $37.24) as part of a pre-agreed trading plan
- Apr 4, 2022SEC Form 4: Thomson Mary Christina exercised 2,000 shares at a strike of $13.04 and sold $70,277 worth of shares (2,000 units at $35.14) as part of a pre-agreed trading plan
- Mar 22, 2022SEC Form 4: Turner William D. exercised 100 shares at a strike of $12.05 and sold $3,705 worth of shares (100 units at $37.05) as part of a pre-agreed trading plan
- Mar 17, 2022SEC Form 4: Turner William D. exercised 3,453 shares at a strike of $12.05 and sold $127,954 worth of shares (3,453 units at $37.06) as part of a pre-agreed trading plan
- Mar 14, 2022SEC Form 4 filed by Dilly Stephen George
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2015
Follow SRRA and get a push notification the moment its next story breaks.